

Summary Public Assessment Report

non-generics

**Inovox 8,75 mg tvrdé pastilky
(flurbiprofen)**

SK/H/0328/001/DC

Date: March 2026

Summary Public Assessment Report

non-generics

Inovox 8,75 mg tvrdé pastilky

flurbiprofen, lozenges, 8,75 mg

This is a summary of the public assessment report (PAR) for Inovox. It explains how Inovox was assessed and its authorisation recommended as well as its conditions of use. It is not intended to provide practical advice on how to use Inovox.

For practical information about using Inovox, patients should read the package leaflet or contact their doctor or pharmacist.

What is Inovox and what is it used for?

Inovox is a ‘hybrid generic medicine’. This means that it is similar to a reference medicine containing the same active substance, but the bioequivalence with the reference medicinal product cannot be demonstrated because it is locally acting medicinal product.

The reference medicine for Inovox is Strepfen Citroen & Honing 8,75 mg, zuigtabletten.

Inovox is used for the local short-term relief of symptoms of sore throat such as throat soreness, pain and swelling, and difficulty in swallowing in adults and adolescents over the age of 12 years.

How does Inovox work?

Inovox contains flurbiprofen. Flurbiprofen belongs to a group of medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) which have analgesic, antipyretic and anti-inflammatory properties.

How is Inovox used?

The pharmaceutical form of Inovox is lozenge and the route of administration is oral.

The recommended dose is:

Adults and adolescents over the age of 12 years:

1 lozenge every 3-6 hours as needed.

Do not take more than 5 lozenges in 24 hours.

Take 1 lozenge and dissolve slowly in the mouth. Always move the lozenge in your mouth while it dissolves.

Please read section 3 of the PL for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can be obtained without a prescription.

What benefits of Inovox have been shown in studies?

Because Inovox is a hybrid application and is considered to be therapeutically equivalent, to the reference product Streptfen Citroen & Honing 8,75 mg, zuiqtabletten, their benefits and risks are taken as being the same as those of the reference medicine.

What are the possible side effects from Inovox?

The most common side effects with Inovox (which may affect more than 1 in 10 people) is inflammation of the mucosa of the oral cavity (stomatitis).

For the full list of all side effects reported with Inovox, see section 4 of the package leaflet.

Why is Inovox approved?

The State Institute for Drug Control decided that Inovox's benefits are greater than its risks and recommended that it be approved for use.

Other information about Inovox

The marketing authorisation for Inovox was granted on 27.10.2025.

The full PAR for Inovox can be found on the website [link](#). For more information about treatment with Inovox, read the package leaflet ([link](#)) or contact your doctor or pharmacist.

This summary was last updated in 03-2026.